Drugs / Motavizumab
Motavizumab
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00192504 | Mar 2004 → Jan 2005 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00192465 | Nov 2003 → Apr 2004 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00113490 | May 2005 → Feb 2006 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00435227 | Mar 2007 → May 2008 | respiratory syncytial virus infectious disease | MedImmune LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00316264 | Apr 2006 → Feb 2007 | lung disorder, respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00538785 | Oct 2005 → Jun 2008 | congenital heart disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00628303 | Oct 2010 → Feb 2011 | asthma | MedImmune LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT00129766 | Nov 2004 → May 2006 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00421304 | Jan 2007 → Sep 2009 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00192478 Comparator | Feb 2004 → May 2006 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00121108 Comparator | Nov 2004 → Dec 2010 | — | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Motavizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00192504 ↗ |
| Known as | MEDI-524 | “The purpose of this study is to determine the safety of motavizumab (MEDI-524) following a single intravenous dose in children hospitalized with respiratory syncytial virus (RSV).” NCT00192504 ↗4“Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season” NCT00316264 ↗ “MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV)” NCT00192478 ↗ |
| Known as | Numax | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743042 ↗ |
| Known as | Numax-TM | “MEDI-524 (Numax-TM)” NCT00192465 ↗ |
| Modality | Monoclonal antibody | “a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV)” NCT00113490 ↗ |
| Route | Intramuscular | “Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.” NCT00113490 ↗ |